Duzallo FDA Approval History
FDA Approved: Yes (Discontinued) (First approved August 18, 2017)
Brand name: Duzallo
Generic name: allopurinol and lesinurad
Dosage form: Tablets
Company: Ironwood Pharmaceuticals, Inc.
Treatment for: Gout
Marketing Status: Discontinued
Duzallo (allopurinol and lesinurad) is a xanthine oxidase inhibitor and URAT1 inhibitor fixed-dose combination for the treatment of hyperuricemia in patients with uncontrolled gout.
On April 15, 2019, the FDA announced the discontinuation of Duzallo (allopurinol and lesinurad). The discontinuation was due to business reasons, and not due to any safety, efficacy or quality issues. The discontinuation was effective as of February 1, 2019.
Development timeline for Duzallo
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
